Shaping the future of sickle cell disease

Majara, a 32-year-old woman from Greenville, North Carolina, in the US, vividly remembers the times when her sickle cell pain crises gripped her body so badly she couldn’t move. “It felt like a dump truck had actually fallen on my body and was just sitting there… Stabbing. I ached all over. There were times where I just wanted the doctor to take away whatever part of my body was hurting,” Majara recounts.

Majara lives with sickle cell disease –a complex and debilitating, genetic blood disorder that goes beyond sickle-shaped red blood cells. The disease is associated with chronic …

/by

Novartis announces FDA and EMA filing acceptance of ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS)

  • Filings are supported by Phase III ASCLEPIOS I and II studies, where ofatumumab showed highly significant and clinically meaningful reduction in the number of confirmed relapses, evaluated as annualized relapse rate (ARR)1
     
  • Ofatumumab is a novel B-cell therapy that delivers sustained efficacy with a favorable safety profile1
     
  • If approved, ofatumumab has the potential to become a first-choice treatment for a broad RMS population and the first B-cell therapy that can be self-administered at home …
/by